JP4359676B2 - Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 - Google Patents

Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 Download PDF

Info

Publication number
JP4359676B2
JP4359676B2 JP2002569851A JP2002569851A JP4359676B2 JP 4359676 B2 JP4359676 B2 JP 4359676B2 JP 2002569851 A JP2002569851 A JP 2002569851A JP 2002569851 A JP2002569851 A JP 2002569851A JP 4359676 B2 JP4359676 B2 JP 4359676B2
Authority
JP
Japan
Prior art keywords
compound
mmol
adenosine
deoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002569851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004522794A5 (https=
JP2004522794A (ja
Inventor
ファン・ティルブルク、エリカ
イジザーマン、アド
Original Assignee
ウニベルジテート・ライデン
キャン−ファイト・バイオファーマ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルジテート・ライデン, キャン−ファイト・バイオファーマ・リミテッド filed Critical ウニベルジテート・ライデン
Publication of JP2004522794A publication Critical patent/JP2004522794A/ja
Publication of JP2004522794A5 publication Critical patent/JP2004522794A5/ja
Application granted granted Critical
Publication of JP4359676B2 publication Critical patent/JP4359676B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2002569851A 2001-03-03 2002-03-03 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用 Expired - Fee Related JP4359676B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105337A GB2372742A (en) 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
PCT/IL2002/000160 WO2002070532A2 (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008310049A Division JP2009167170A (ja) 2001-03-03 2008-12-04 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用

Publications (3)

Publication Number Publication Date
JP2004522794A JP2004522794A (ja) 2004-07-29
JP2004522794A5 JP2004522794A5 (https=) 2005-06-30
JP4359676B2 true JP4359676B2 (ja) 2009-11-04

Family

ID=9909952

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002569851A Expired - Fee Related JP4359676B2 (ja) 2001-03-03 2002-03-03 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用
JP2008310049A Pending JP2009167170A (ja) 2001-03-03 2008-12-04 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008310049A Pending JP2009167170A (ja) 2001-03-03 2008-12-04 Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用

Country Status (9)

Country Link
US (2) US7084127B2 (https=)
EP (1) EP1368365A2 (https=)
JP (2) JP4359676B2 (https=)
KR (1) KR100585894B1 (https=)
CN (1) CN1259332C (https=)
AU (1) AU2002234851A1 (https=)
CA (1) CA2439879C (https=)
GB (1) GB2372742A (https=)
WO (1) WO2002070532A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527502A (ja) * 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシン受容体の部分的および全アゴニスト
JP2005132767A (ja) * 2003-10-30 2005-05-26 Sumitomo Chemical Co Ltd プリン化合物の製造方法
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2009231978C1 (en) * 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
EP2331542B1 (en) * 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
WO2014068589A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
EP3448015B1 (en) * 2016-04-22 2021-11-24 Kowa Company, Ltd. Image capturing device provided with multiplexer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias

Also Published As

Publication number Publication date
AU2002234851A1 (en) 2002-09-19
US7084127B2 (en) 2006-08-01
WO2002070532A3 (en) 2002-11-28
CA2439879A1 (en) 2002-09-12
US7189706B2 (en) 2007-03-13
GB2372742A (en) 2002-09-04
KR20030089512A (ko) 2003-11-21
US20040127452A1 (en) 2004-07-01
CN1259332C (zh) 2006-06-14
EP1368365A2 (en) 2003-12-10
WO2002070532A2 (en) 2002-09-12
JP2009167170A (ja) 2009-07-30
JP2004522794A (ja) 2004-07-29
CN1537115A (zh) 2004-10-13
KR100585894B1 (ko) 2006-06-07
CA2439879C (en) 2009-09-15
US20040132686A1 (en) 2004-07-08
GB0105337D0 (en) 2001-04-18

Similar Documents

Publication Publication Date Title
JP2009167170A (ja) Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用
TWI620755B (zh) 作為流感病毒ｒｎａ複製之抑制劑之經４’－二氟甲基取代之核苷衍生物
JP4931683B2 (ja) Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
JP4294870B2 (ja) Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
AU678053B2 (en) Chemical compounds, their preparation and use
EP1478322A2 (en) Beta-2'-OR 3'-HALONUCLEOSIDES
KR20050109918A (ko) 2'-분지형 뉴클레오시드의 제조 방법
KR20030061792A (ko) 뉴클레오시드 유도체
ZA200309169B (en) 4 substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
MX2011006892A (es) Sintesis de nucleosidos de purina.
EP0708781A1 (en) A 3 adenosine receptor agonists
EP1765844A2 (en) Purine nucleotide derivatives
WO2018199048A1 (ja) ヌクレオシド系抗がん剤または抗ウィルス剤の５'位モノ燐酸ジベンジルエステル誘導体
US7112574B2 (en) C2,8-disubstituted adenosine derivatives and their different uses
WO1997033591A1 (en) A method of treating disorders related to cytokines in mammals
Tsoukala et al. Keto and exomethylene pyranonucleosides as antitumor agents
Bozhok et al. Synthesis of novel 6-substituted thymine ribonucleosides and their 3′-fluorinated analogues
CN1911237B (zh) 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
Zhong N9 Alkylation and Glycosylation of Purines: A Practical Synthesis of 2-Chloro-2'-Deoxyadenosine
HK1165429A (en) Synthesis of purine nucleosides
TW201210602A (en) Phosphorus-containing prodrugs and their therapeutic use

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090616

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090716

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120821

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees